Literature DB >> 20621467

EORTC Melanoma Group sentinel node protocol identifies high rate of submicrometastases according to Rotterdam Criteria.

Augustinus P T van der Ploeg1, Alexander C J van Akkooi, Paul I M Schmitz, Senada Koljenovic, Cornelis Verhoef, Alexander M M Eggermont.   

Abstract

Sentinel node (SN) status is the most important prognostic factor for disease-free survival (DFS) and overall survival (OS) in stages I-II melanoma. We evaluated the positive sentinel node identification rate of the EORTC Melanoma Group (MG) protocol as well as its capacity to identify minimal tumour burden, according to the Rotterdam Criteria in 421 consecutive patients. Correlations between primary tumour characteristics and SN tumour burden were investigated. The same 2 pathologists worked up all SNs according to the EORTC MG protocol and tumour burden was scored according to the Rotterdam Criteria (<0.1 mm, 0.1-1.0 mm and >1.0 mm for the largest diameter of the largest metastasis in the SN). The positive SN detection rate was 28.7% with a false negative rate of 10.4% at a median Breslow thickness of 2.1 mm. The high positive identification rate of about 30% of the EORTC MG protocol has been confirmed in this study. The protocol is sensitive and identifies submicrometastases (<0.1 mm) in a high percentage (18%). The variables SN tumour load, non-SN (NSN) status and ulceration of the primary were independent prognostic factors for DFS and OS in the multivariate analysis. At a median follow-up time of 4.3 years patients with minimal tumour burden (<0.1 mm) had a 5 year OS rate of 91%, virtually identical to 90% for SN-negative patients. The NSN positivity rate of 0% in these patients indicates that they may be spared a completion lymph node dissection (CLND) and its morbidity. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20621467     DOI: 10.1016/j.ejca.2010.06.003

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  9 in total

Review 1.  Tissue prognostic biomarkers in primary cutaneous melanoma.

Authors:  Mario Mandalà; Daniela Massi
Journal:  Virchows Arch       Date:  2014-02-01       Impact factor: 4.064

2.  Completion lymphadenectomy for sentinel node positive cutaneous head & neck melanoma.

Authors:  Cecelia E Schmalbach; Carol R Bradford
Journal:  Laryngoscope Investig Otolaryngol       Date:  2018-02-05

3.  Gamma probe and ultrasound guided fine needle aspiration cytology of the sentinel node (GULF) trial - overview of the literature, pilot and study protocol.

Authors:  Charlotte M C Oude Ophuis; Lisa B Koppert; Cécile de Monyé; Carolien H M van Deurzen; Senada Koljenović; Alexander C J van Akkooi; Cornelis Verhoef; Dirk J Grünhagen
Journal:  BMC Cancer       Date:  2017-04-12       Impact factor: 4.430

4.  Evolving management of positive regional lymph nodes in melanoma: Past, present and future directions.

Authors:  Rachel A Fayne; Francisco I Macedo; Steven E Rodgers; Mecker G Möller
Journal:  Oncol Rev       Date:  2019-11-28

5.  Sentinel Lymph Node Biopsy in Head and Neck Melanoma: Long-term Outcomes, Prognostic Value, Accuracy, and Safety.

Authors:  John E Hanks; Kevin J Kovatch; S Ahmed Ali; Emily Roberts; Alison B Durham; Joshua D Smith; Carol R Bradford; Kelly M Malloy; Philip S Boonstra; Christopher D Lao; Scott A McLean
Journal:  Otolaryngol Head Neck Surg       Date:  2020-02-11       Impact factor: 3.497

6.  Decoding melanoma metastasis.

Authors:  William E Damsky; Lara E Rosenbaum; Marcus Bosenberg
Journal:  Cancers (Basel)       Date:  2010-12-30       Impact factor: 6.639

7.  Quantitative measurement of melanoma spread in sentinel lymph nodes and survival.

Authors:  Anja Ulmer; Klaus Dietz; Isabelle Hodak; Bernhard Polzer; Sebastian Scheitler; Murat Yildiz; Zbigniew Czyz; Petra Lehnert; Tanja Fehm; Christian Hafner; Stefan Schanz; Martin Röcken; Claus Garbe; Helmut Breuninger; Gerhard Fierlbeck; Christoph A Klein
Journal:  PLoS Med       Date:  2014-02-18       Impact factor: 11.069

8.  Validation of a clinicopathological and gene expression profile model for sentinel lymph node metastasis in primary cutaneous melanoma.

Authors:  E E A P Mulder; J T Dwarkasing; D Tempel; A van der Spek; L Bosman; D Verver; A L Mooyaart; A A M van der Veldt; C Verhoef; T E C Nijsten; D J Grunhagen; L M Hollestein
Journal:  Br J Dermatol       Date:  2020-11-02       Impact factor: 9.302

9.  The sentinel node invasion level (SNIL) as a prognostic parameter in melanoma.

Authors:  Lutz Kretschmer; Christina Mitteldorf; Simin Hellriegel; Andreas Leha; Alexander Fichtner; Philipp Ströbel; Michael P Schön; Felix Bremmer
Journal:  Mod Pathol       Date:  2021-06-15       Impact factor: 7.842

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.